Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I safety, tolerability, and pharmacokinetics of single IV OJI-220 in healthy Japanese adult males
jRCT2071260003Phase 1Recruiting
- Sponsor
- Oji Pharma
- Start
- Apr 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of OJI-220 in normal, sponsored by Oji Pharma. Primary endpoint: Safety and tolerability. Started Apr 2026; status: recruiting.
02
Drugs
OJI-220
03
Conditions
normal
Beyond the preview
Go deeper on jRCT2071260003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071260003.